Trading volume has spiked for most public companies
Three psychedelic stocks have been setting the pace
Summer is over. But psychedelic drug stocks are starting to heat up.
Major news has driven much higher trading volumes.
Compass Pathways (US:CMPS) has made its IPO debut. And it raised a whopping $146.6 million for its IPO financing.
MindMed Inc (CAN:MMED / US:MMEDF) has announced its application to up-list on the NASDAQ. With the most advanced R&D portfolio among public companies, the added financial punch of a NASDAQ listing could really launch this stock – as it has already done with CMPS.
Smaller Mind Cure Health (CAN:MCUR) commenced trading a day after Compass Pathways. But $MCUR has outperformed even CMPS to date.
While volume is up across the sector, these three companies have translated that increased investor interest into the biggest gains.
Something for everyone
As an emerging sector, prudent investors will want to spread around their psychedelics investing dollars – to mitigate risk.
Together, these Three Musketeers of the psychedelics space could comprise a mini-psychedelics portfolio by themselves, since each brings something different to the table.
Compass Pathways is the Big Dog. US/UK based. High profile investors. Well capitalized. NASDAQ listing.
MindMed Inc is (at this stage) the Research Leader among public companies as psychedelic drugs emerge from the shadows – after 50 years of drug Prohibition. Second to Compass among the pubcos in raising capital. Second to Compass in terms of high-profile investors.
Mind Cure Health is the High-Growth Microcap. Unlike CMPS and MMED, Mind Cure (MCUR) has a hybrid business model: functional mushrooms (first) as a stepping stone to psychedelic drug clinical research.
The Big Dog
Emerging sectors need a bellwether. An industry leader to focus attention and rally support for the industry as a whole.
It’s quickly becoming apparent that Compass Pathways is filling that role for the psychedelics space.
Expected to do its IPO financing between $14 - $16 per share, CMPS began trading at $17 – and took off from there. Now trading at $42.90, a nice 146% IPO profit.
Not a big surprise. CMPS ticks all the boxes for aggressive investors looking for the next opportunity with unicorn potential.
- Silicon Valley and Wall Street icons (like Peter Thiel and Mike Novogratz) are leading investors in CMPS, lending it instant credibility.
- Well capitalized. Even before going public, Compass has had no difficulty raising money, including $80 million in its Series B financing alone.
- Its Phase 2 clinical trial using psilocybin-based therapy for treatment-resistant depression is the best-positioned drug trial in the industry – thanks to Breakthrough Therapy Designation from the FDA.
- Premier public listing. Going public on the NASDAQ was the icing on the cake for investors.
There is more than just hype and big names to this story.
Globally, depression afflicts well over 300 million people – with those numbers spiraling due to the many stresses of the COVID-19 pandemic. Front-line drugs to treat depression deliver abysmal efficacy.
Yet Big Pharma has largely walked away from R&D for mental health-related drug therapies. This leaves the playing field wide open for psychedelic drug startups.
Clinical trials are already providing strong indications that psychedelic drugs could (will?) become the new standard of care. Not only for depression, but also for anxiety, addiction, PTSD and perhaps several more common medical disorders.
Do psychedelic drug companies offer unicorn potential for investors? With CMPS, we can now scratch the word “potential”.
When Compass Pathways closed its IPO financing, it sat with a market cap of $1.3 billion.
Where will the next billion-dollar market cap come from?
The Research Leader
It could very well be MindMed Inc.
Compass Pathways has the best (individual) clinical trial initiative in the psychedelic drug industry today. But MindMed has the most research at the clinical trials level – by a large margin.
MMED has three clinical trials program that have reached Phase 2. Testing microdoses of LSD to treat adult ADHD. Another LSD-based clinical trial to treat cluster headaches. And a third LSD-based program for an anxiety treatment.
MindMed has several other clinical trials into Phase 1 of testing. This includes 18-MC, a non-psychoactive ibogaine derivative to treat opioid addiction. And its about to commence the first-ever clinical trial to combine LSD and MDMA as a drug therapy.
Forging this industry-leading research platform (in collaboration with the University of Basel, Switzerland) has earned MindMed some high-profile support.
Bruce Linton, cannabis pioneer and former CEO of Canopy Growth Corp is on the MindMed board. High-profile Canadian analyst and investor Kevin O’Leary is also a major shareholder.
MindMed lags well behind Compass Pathways in raising capital (~US$40 million to date). But it’s well ahead of other public companies. A new NASDAQ listing would dramatically improve its access to capital markets.
After months of sideways trading, MMED has broken out on two catalysts – the excitement generated by the Compass IPO and its own up-listing application. The stock has taken off from CAD$0.44 to CAD$0.94.
This may just be the start.
The High-Growth Microcap
Compass Pathways and MindMed Inc are obvious additions to almost any psychedelics-based investing portfolio.
Mind Cure Health? Not nearly as obvious a choice. But with one less trading day under its belt, MCUR stock is already outperforming even the Big Dog.
Mind Cure started trading last Monday, at an IPO price of CAD$0.20 and a lean market cap below CAD$10 million. But that has quickly swollen after a sizzling first week of trading.
Now sitting at CAD$0.72, its market cap has risen to CAD$32.6 million. That’s a 260% spike in the first week of trading.
What has gotten investors excited? Mushrooms.
Not magic mushrooms, not yet.
Functional mushrooms. Nootropics.
Psychedelic drugs have grabbed a lot of headlines for their potential to disrupt a number of multi-billion dollar treatment markets.
Functional mushrooms are a multi-billion-dollar market with revenue streams that are up for grabs today. A $23 billion market, growing to $37 billion by 2025, according to Mordor Intelligence.
Mind Cure’s Moonbeam product line of organic functional mushrooms already has its Health Canada Authorization (and Natural Product Numbers) to commence commercial retailing in Canada.
Why build a business model as functional mushrooms/psychedelic drug hybrid? Strong synergies.
Psychedelic drugs are achieving great success in clinical testing for stress-related mental health disorders like depression, anxiety, addiction and PTSD. Reishi mushrooms are being touted for their capacity to reduce stress – and thus help prevent stress-related disorders.
Psychedelics-based research is also advancing with respect to cognitive decline – another huge part of the Mental Health Crisis. Nutritional supplements experts like Paul Stamets cite clinical research showing that Lion’s Mane mushrooms can halt and even reverse the neural damage that leads to Alzheimer’s disease.
Mind Cure already has a Reishi mushroom and Lion’s Mane mushroom formulation for its Moonbeam product line. It is also preparing to market a Turkey Tail mushroom formulation.
Turkey Tail is known for its immune-boosting properties. Thanks to a little thing known as “COVID-19” immune-system support is a top priority with nutritional supplements consumers.
This revenue potential is accessible today – and can help significantly offset the burn rate once Mind Cure commences its own psychedelics-based R&D. Strong synergies with psychedelic drugs.
It’s a business strategy that is clearly resonating with investors.
But Mind Cure is already looking even further road. Management sees a day when biohacking with functional mushrooms and microdosing with psychedelic drugs merges – and forms a much larger market.
Microdosing with psychedelic drugs is already a hot trend even in advance of these substances being legalized for consumption.
We’ll explore this subject in greater depth in an upcoming feature on Mind Cure.
The train is leaving the station
Psychedelic stocks are hot – again. This comes even as broader markets have seen some steep selloffs in choppy trading.
At the moment, a trio of stocks are powering most of the investor gains.
As investors build a psychedelics portfolio to capitalize on opportunities in mental health treatment, due diligence should probably start with these Three Musketeers.
DISCLOSURE: The writer holds shares in MindMed Inc and Mind Cure Health. Mind Cure Health is a client of Psychedelic Stock Watch.
Report: Upstart Mind Cure (CSE:MCUR) Set To Disrupt $300 Billion Industry Psychedelic IPO
The content on Psychedelic Stock Watch is not personalized investment advice. Our employees strive to give smart, stimulating commentary, but are not licensed to address or give advice on individual investment situations. Nothing you receive from Psychedelic Stock Watch should be considered personal investment advice. Any investments recommended by Psychedelic Stock Watch should only be made after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. All investments carry risk of significant loss.
Please see full disclaimers at https://psychedelicstockwatch.com/ applicable to all content provided by PSW , wherever published or re-published: https://psychedelicstockwatch.com/statements-policies
Disclaimer: This release/advertorial is a commercial advertisement and is for general information purposes only. This release/advertorial does not constitute an offer or solicitation to buy or sell any securities or individualized investment advice. This is a native advertisement, meaning it is an informational paid marketing piece. PsychedelicStockWatch.com (PSW) makes no recommendation that the securities of the issuers profiled or discussed on this website should be purchased, sold or held by viewers, whether or not viewers learn of the profiled issuers through our website or otherwise. Please review all investment decisions with a licensed investment advisor.
PSW receives media support and payments from the issuer or third-party companies that have contracted with the issuer ranging from approximately $25,000 to $150,000 to publish and/or distribute advertisements on behalf of the issuer. The issuer and/or third-party companies that have contracted with the issuer have not promised exclusivity to PSW and may hire additional publishers or advertisers on behalf of the issuer. PSW retains any excess sums after expenses as its compensation. PSW may be paid for services using cash, options, restricted shares, free-trading shares, or shares of other unrelated issuers, and thus PSW and its owners, operators and affiliates may benefit from any increase in the share prices of the profiled issuers.
PSW and/or its owners, operators and affiliates make no representations about their short-term or long-term investment horizons and may be selling shares of stock at the same time the profile (or other information) is being disseminated to potential investors; PSW is under no obligation to, and will not, advise any party when it or its affiliates decide to buy or sell shares. Investors must make all investment decisions based on their own judgment of the market and the particular securities.
This release/advertorial contains forward-looking statements that involve risks and uncertainties. This release/advertorial contains or incorporates by reference forward-looking statements, including certain information with respect to plans and strategies of the featured issuer. As such, any statements contained herein or incorporated herein by reference that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words “believe(s),” “anticipate(s),” “plan(s),” “expect(s),” “project(s),” “will,” “make,” “told,” “could,” “might,” and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause actual events or actual results of the issuer to differ materially from these indicated by such forward-looking statements. Certain statements contained herein are forward-looking statements as defined in Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Such statements include, without limitation, statements regarding business, financing, business trends, future operating revenues and expenses. There can be no assurance that such expectations will prove to be correct. Investors are cautioned that any forward-looking statements made by the issuer or PSW or contained in this release/advertorial are not guarantees of future performance, and that the issuer’s actual results may differ materially from those set forth in the forward-looking statements. We undertake no obligation to update any statements made herein. Differences in results can be caused by various factors including, but not limited to, the issuer’s ability to be able to successfully complete planned funding agreements, to successfully market its products in competitive industries or to effectively implement its business plan or strategies. To reiterate, information presented in this release/advertorial contains “forward-looking statements.” Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact and may be “forward-looking statements.” Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. More information on the issuer that is the subject of this release/advertorial may be found at http://www.sec.gov where readers can review all public filings submitted by the issuer. PSW is not a certified financial analyst, investment advisor, broker/dealer, or licensed in the securities industry in any manner. The information in this advertorial is subjective opinion and may not be complete, accurate or current and was paid for by the issuer, creating a potential conflict of interest.